BACKGROUND: Research into the association between diabetes and pulmonary function has resulted in inconsistent outcomes among studies. We performed a metaanalysis to clarify this association. METHODS: From a systematic search of the literature, we included 40 studies describing pulmonary function data of 3,182 patients with diabetes and 27,080 control subjects. Associations were summarized pooling the mean difference (MD) (standard error) between patients with diabetes and control subjects of all studies for key lung function parameters. RESULTS: For all studies, the pooled MD for FEV(1), FVC, and diffusion of the lungs for carbon monoxide were -5.1 (95% CI, -6.4 to -3.7; P < .001), -6.3 (95% CI, -8.0 to -4.7; P < .001), and -7.2 (95% CI, -10.0 to -4.4; P < .001) % predicted, respectively, and for FEV(1)/FVC 0.1% (95% CI, -0.8 to 1.0; P = .78). Metaregression analyses showed that between-study heterogeneity was not explained by BMI, smoking, diabetes duration, or glycated hemoglobin (all P > .05). CONCLUSIONS: Diabetes is associated with a modest, albeit statistically significant, impaired pulmonary function in a restrictive pattern. Since our results apply to the diabetic subpopulation free from overt pulmonary disease, it would next be interesting to investigate the potential clinical implications in those patients with diabetes who carry a pulmonary diagnosis, such as COPD or asthma.
BACKGROUND: Research into the association between diabetes and pulmonary function has resulted in inconsistent outcomes among studies. We performed a metaanalysis to clarify this association. METHODS: From a systematic search of the literature, we included 40 studies describing pulmonary function data of 3,182 patients with diabetes and 27,080 control subjects. Associations were summarized pooling the mean difference (MD) (standard error) between patients with diabetes and control subjects of all studies for key lung function parameters. RESULTS: For all studies, the pooled MD for FEV(1), FVC, and diffusion of the lungs for carbon monoxide were -5.1 (95% CI, -6.4 to -3.7; P < .001), -6.3 (95% CI, -8.0 to -4.7; P < .001), and -7.2 (95% CI, -10.0 to -4.4; P < .001) % predicted, respectively, and for FEV(1)/FVC 0.1% (95% CI, -0.8 to 1.0; P = .78). Metaregression analyses showed that between-study heterogeneity was not explained by BMI, smoking, diabetes duration, or glycated hemoglobin (all P > .05). CONCLUSIONS:Diabetes is associated with a modest, albeit statistically significant, impaired pulmonary function in a restrictive pattern. Since our results apply to the diabetic subpopulation free from overt pulmonary disease, it would next be interesting to investigate the potential clinical implications in those patients with diabetes who carry a pulmonary diagnosis, such as COPD or asthma.
Authors: Emily S Wan; John E Hokanson; James R Murphy; Elizabeth A Regan; Barry J Make; David A Lynch; James D Crapo; Edwin K Silverman Journal: Am J Respir Crit Care Med Date: 2011-04-14 Impact factor: 21.405
Authors: Rachel Yoon Kyung Chang; Philip Chi Lip Kwok; Sussan Ghassabian; John D Brannan; Heikki O Koskela; Hak-Kim Chan Journal: Br J Pharmacol Date: 2020-08-07 Impact factor: 8.739
Authors: Dario Pitocco; Leonello Fuso; Emanuele G Conte; Francesco Zaccardi; Carola Condoluci; Giuseppe Scavone; Raffaele A Incalzi; Giovanni Ghirlanda Journal: Rev Diabet Stud Date: 2012-05-10
Authors: Ismail L Mohamad; Khaled Saad; Ali Abdel-Azeem; Sherif A A Mohamed; Hisham A K Othman; Khaled A Abdel Baseer; Ahmad F Thabet; Amira A El-Houfey Journal: Ther Adv Endocrinol Metab Date: 2015-06 Impact factor: 3.565
Authors: Oana L Klein; Larissa Aviles-Santa; Jianwen Cai; Harold R Collard; Alka M Kanaya; Robert C Kaplan; Gregory L Kinney; Eliana Mendes; Lewis Smith; Gregory Talavera; Donghong Wu; Martha Daviglus Journal: Diabetes Care Date: 2016-09-09 Impact factor: 19.112
Authors: Matthew A Schechter; Asad A Shah; Brian R Englum; Judson B Williams; Asvin M Ganapathi; John D Davies; Ian J Welsby; G Chad Hughes Journal: J Crit Care Date: 2015-11-06 Impact factor: 3.425